Enders Frederik, Geisenberger Christoph, Jungk Christine, Bermejo Justo Lorenzo, Warta Rolf, von Deimling Andreas, Herold-Mende Christel, Unterberg Andreas
Department of Neurosurgery, University Hospital Heidelberg, Germany.
Department of Neurosurgery, University Hospital Heidelberg, Germany.
Clin Neurol Neurosurg. 2016 Mar;142:72-80. doi: 10.1016/j.clineuro.2016.01.011. Epub 2016 Jan 14.
Brain metastases (BMs) are the most common malignant brain tumors in adults. Despite multimodal treatment options such as microsurgery, radiotherapy and chemotherapy, prognosis still remains very poor. Non-small cell lung cancer (NSCLC) constitutes the most common source of brain metastases. In this study, prognostic factors in this patient population were identified through an in-depth analysis of clinical parameters of patients with BMs from NSCLC.
Clinical data of 114 NSCLC cancer patients who underwent surgery for BMs at the University Hospital Heidelberg were retrospectively reviewed for age, gender, type of treatment, time course of the disease, presence of neurologic symptoms, Karnofsky Performance Status (KPS), smoking history, presence of extracranial metastases at initial diagnosis of NSCLC, number, location and size of brain metastases. Univariate and multivariate survival analyses were performed using the Log-rank test and Cox' proportional hazard model, respectively.
Median survival time from surgery for BMs was 11.2 months. 18.4% (21 of 114) patients were long-term survivors (>24 months; range 26.3-75.1 months). Age, gender, size and number of intracranial metastases were not significantly associated with patient survival. Univariate analysis identified complete resection, postoperative whole brain radiotherapy (WBRT) and a preoperative KPS of >80% as positive prognostic factors. Infratentorial location and presence of extracranial metastases were shown to be negative prognostic factors. Surgery for the primary tumor was associated with a superior patient outcome both in univariate and multivariate analyses.
Our data strongly suggest that surgical treatment of the primary tumor and complete resection of brain metastases in NSCLC patients followed by WBRT improve survival. Moreover, long-term survivors (>2 years) were more frequent than previously reported.
脑转移瘤(BMs)是成人中最常见的恶性脑肿瘤。尽管有显微手术、放疗和化疗等多模式治疗选择,但预后仍然很差。非小细胞肺癌(NSCLC)是脑转移瘤最常见的来源。在本研究中,通过对NSCLC脑转移瘤患者临床参数的深入分析,确定了该患者群体的预后因素。
回顾性分析海德堡大学医院114例接受BMs手术的NSCLC患者的临床资料,包括年龄、性别、治疗类型、疾病病程、神经症状的存在、卡氏功能状态(KPS)、吸烟史、NSCLC初诊时颅外转移的存在、脑转移瘤的数量、位置和大小。分别使用对数秩检验和Cox比例风险模型进行单因素和多因素生存分析。
BMs手术后的中位生存时间为11.2个月。18.4%(114例中的21例)患者为长期幸存者(>24个月;范围26.3 - 75.1个月)。年龄、性别、颅内转移瘤的大小和数量与患者生存无显著相关性。单因素分析确定完全切除、术后全脑放疗(WBRT)和术前KPS>80%为阳性预后因素。幕下位置和颅外转移的存在被证明是阴性预后因素。在单因素和多因素分析中,原发肿瘤手术均与更好的患者预后相关。
我们的数据强烈表明,NSCLC患者原发肿瘤的手术治疗和脑转移瘤的完全切除,随后进行WBRT可提高生存率。此外,长期幸存者(>2年)比以前报道的更常见。